Survivals following discontinuation of PD-1 inhibitor treatment in advanced melanoma patients
Sign Up to like & getrecommendations! Published in 2022 at "Melanoma Research"
DOI: 10.1097/cmr.0000000000000858
Abstract: The aim of this study was to evaluate overall survival post-treatment discontinuation survival (OSPTD) in advanced melanoma patients started on immunotherapy. This retrospective study included all unresectable advanced or metastatic melanoma patients who had permanent… read more here.
Keywords: completion; inhibitor treatment; toxicity; discontinuation ... See more keywords
Baseline clinical features predicting macrophage activation syndrome in patients with systemic adult‐onset Still’s disease receiving interleukin‐6 inhibitor treatment
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Rheumatic Diseases"
DOI: 10.1111/1756-185x.14371
Abstract: Macrophage activation syndrome (MAS), a severe complication of systemic adult‐onset Still’s disease (AOSD), has been reported to occur during interleukin‐6 (IL‐6) inhibitor treatment. However, predictors for MAS development are unknown. Therefore, this study investigated predictive… read more here.
Keywords: macrophage activation; inhibitor treatment; activation syndrome; inhibitor ... See more keywords
Loss of Dnmt3a impairs hematopoietic homeostasis and myeloid cell skewing via the PI3Kinase pathway.
Sign Up to like & getrecommendations! Published in 2023 at "JCI insight"
DOI: 10.1172/jci.insight.163864
Abstract: Loss-of-function mutations in the DNA methyltransferase 3A (DNMT3A) are seen in a large number of patients with acute myeloid leukemia (AML) with normal cytogenetics and are frequently associated with poor prognosis. DNMT3A mutations are an… read more here.
Keywords: cell; inhibitor treatment; pi3k inhibitor; loss ... See more keywords
Osilodrostat: 11β-hydroxylase inhibitor for treatment of Cushing's disease.
Sign Up to like & getrecommendations! Published in 2020 at "Drugs of today"
DOI: 10.1358/dot.2020.56.10.3182908
Abstract: Osilodrostat was synthesized in a search for a drug that would inhibit the synthesis of aldosterone, with the aim to discover a new approach for treating hypertension. However, early clinical trials revealed that the doses… read more here.
Keywords: cushing disease; inhibitor; osilodrostat hydroxylase; hydroxylase inhibitor ... See more keywords
Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2020.00515
Abstract: Immunotherapies in tumors have attracted increasing attention. They play an important role in precision medicine. Many immune-checkpoint inhibitors (ICIs) have obtained FDA approval and show good performance in the clinic. Hyperprogressive disease (HPD) after ICIs… read more here.
Keywords: immune checkpoint; treatment characteristics; inhibitor treatment; hyperprogression immune ... See more keywords
Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment
Sign Up to like & getrecommendations! Published in 2018 at "Biomedicines"
DOI: 10.3390/biomedicines6010026
Abstract: Targeting the immune checkpoint receptors cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed cell death 1 ligand 1 (PD-L1) represents a very attractive treatment modality for tumor patients. The… read more here.
Keywords: ctla inhibitor; prior ctla; inhibitor; treatment ... See more keywords
Systematic review of mTOR inhibitor treatment, biomarkers and prophylaxis for tuberous sclerosis complex-associated seizures.
Sign Up to like & getrecommendations! Published in 2022 at "Clinical medicine"
DOI: 10.7861/clinmed.22-4-s48
Abstract: Long-term safety: 94% of 48 TSC patients with refractory epilepsy maintained improved seizure control over 4 years; safe and tolerable. Adverse effects decreased over time. White matter modification: Everolimus pharmacologically modifies the genetic defect of… read more here.
Keywords: review mtor; inhibitor treatment; treatment biomarkers; systematic review ... See more keywords